Corticosteroid and calcineurin inhibitor sparing regimens in kidney transplantation

被引:4
|
作者
Cortazar, Frank [1 ]
Diaz-Wong, Roque [2 ]
Roth, David [2 ]
Isakova, Tamara [2 ]
机构
[1] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA
[2] Univ Miami, Miller Sch Med, Dept Med, Div Nephrol & Hypertens, Miami, FL 33136 USA
基金
美国国家卫生研究院;
关键词
belatacept; corticosteroids; mammalian target of rapamycin inhibitors; RENAL-ALLOGRAFT RECIPIENTS; MYCOPHENOLATE-MOFETIL; PHASE-III; LONG-TERM; STEROID WITHDRAWAL; BENEFIT-EXT; BELATACEPT; SIROLIMUS; CYCLOSPORINE; IMMUNOSUPPRESSION;
D O I
10.1093/ndt/gft231
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Chronic kidney disease is a major public health problem that is associated with increased risks of kidney disease progression, cardiovascular disease and death. Kidney transplantation remains the renal replacement therapy of choice for patients with end-stage kidney disease. Despite impressive strides in short-term allograft survival, there has been little improvement in long-term kidney graft survival, and rates of death with a functioning allograft remain high. Long-term safety profiles of existing immunosuppressive regimens point to a need for continued search for alternative agents. This overview discusses emerging evidence on a few promising therapeutic approaches, juxtaposes conflicting findings and highlights remaining knowledge gaps.
引用
收藏
页码:2708 / 2716
页数:9
相关论文
共 50 条
  • [21] Enhancing Beta Cell Replacement Therapies: Exploring Calcineurin Inhibitor-Sparing Immunosuppressive Regimens
    Caldara, Rossana
    Tomajer, Valentina
    Piemonti, Lorenzo
    [J]. TRANSPLANT INTERNATIONAL, 2023, 36
  • [22] Role of daclizumab as a calcineurin inhibitor-sparing agent following heart transplantation.
    Namba, JM
    Kenyon, KW
    Fishbein, DP
    [J]. PHARMACOTHERAPY, 2005, 25 (10): : 1490 - 1491
  • [23] Calcineurin inhibitor sparing in paediatric solid organ transplantation - Managing the efficacy/toxicity conundrum
    Tredger, J. Michael
    Brown, Nigel W.
    Dhawan, Anil
    [J]. DRUGS, 2008, 68 (10) : 1385 - 1414
  • [24] INCIDENCE AND FACTORS ASSOCIATED WITH CALCINEURIN INHIBITOR NEPHROTOXICITY IN PEDIATRIC KIDNEY TRANSPLANTATION
    Pavarojkit, Pavaree
    Srisuwan, Konggrapun
    [J]. NEPHROLOGY, 2023, 28 : 72 - 73
  • [25] A noninferiority design for a delayed calcineurin inhibitor substitution trial in kidney transplantation
    Nickerson, Peter W.
    Balshaw, Robert
    Wiebe, Chris
    Ho, Julie
    Gibson, Ian W.
    Bridges, Nancy D.
    Rush, David N.
    Heeger, Peter S.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 (04) : 1503 - 1512
  • [26] Calcineurin inhibitor minimization, withdrawal and avoidance protocols after kidney transplantation
    Haller, Maria
    Oberbauer, Rainer
    [J]. TRANSPLANT INTERNATIONAL, 2009, 22 (01) : 69 - 77
  • [27] Patient selection critical for calcineurin inhibitor withdrawal in pediatric kidney transplantation
    Weintraub, Lauren
    Li, Li
    Kambham, Neeraja
    Alexander, Steven
    Concepcion, Waldo
    Miller, Kim
    Wong, Cynthia
    Salvatierra, Oscar
    Sarwal, Minnie
    [J]. PEDIATRIC TRANSPLANTATION, 2008, 12 (05) : 541 - 549
  • [28] Rationale and criteria of eligibility for calcineurin inhibitor interruption following kidney transplantation
    Danger, Richard
    Giral, Magali
    Soulillou, Jean-Paul
    Brouard, Sophie
    [J]. CURRENT OPINION IN ORGAN TRANSPLANTATION, 2008, 13 (06) : 609 - 613
  • [29] Conversion from Calcineurin Inhibitor to Sirolimus in Kidney Transplantation Recipients with Malignancy
    Yoon, J.
    Kang, S.
    Kim, S.
    Baeck, C.
    Kim, H.
    Park, S. -K.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 744 - 744
  • [30] Calcineurin-inhibitor-sparing immunosuppressive protocols
    Bestard, O
    Cruzado, JM
    Grinyó, JM
    [J]. TRANSPLANTATION PROCEEDINGS, 2005, 37 (09) : 3729 - 3732